BioSpace News Archive

Biosenta Inc. (“Biosenta” or the “Company”) listed on the CSE (CSE:ZRO) announces that it will enter into a series of prime plus 5% unsecured promissory notes (the “Notes”) in consideration for cash investments in the aggregate amount of $85,000 (together, the “Investment”).

On Tuesday, January 26th, Governor Andy Beshear’s office announced that the first two cases of a more contagious variant of coronavirus, first identified in the United Kingdom, have been confirmed in Kentucky.

The pet cancer therapeutics market is likely to witness sizable revenue growth on account of rising consumer spending on pet healthcare.

The pH meters market growth is a result of the growing incidences of food adulteration in developing as well as developed countries.

The influx of the latest technologies and the spike in the number of birth rates worldwide will influence point of care ultrasound market trends over the coming years.

Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (

The oxygen cylinders and concentrators market is projected to record tremendous growth on account of rising elderly population base that is mostly prone to chronic respiratory diseases like asthma, pulmonary, and COPD.

Growing cases of influenza and chronic disorders such as diabetes and cardiovascular diseases will fuel rapid influenza diagnostic tests (RIDT) market share in the coming years.

Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the “Trial”) of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil .

Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clini